We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biotech Company Develops from Laboratory and Clinical Studies

By LabMedica International staff writers
Posted on 04 Aug 2010
A new biotech company aims to improve the diagnosis of diabetes and cancer.

The startup company, which developed from diabetes and genomic research, will offer biomedical institutions and pharmaceutical industries, services and research reagents. More...


Providing a variety of high-throughput scientific services the new company, Jinfiniti Biosciences, LLC is housed in the Medical College of Georgia (MCG) Life Sciences Business Development Center (Augusta, GA, USA). It offers nucleic acid isolation, genomic analysis, antibody production, immunoassays, medicinal chemistry, toxicity evaluation for clinical laboratories, academic and pharmaceutic institutions, and forensics.

Biomarkers are also being developed that will enable the introduction of simple urine and/or blood tests for early disease detection, diagnosis, and monitoring of treatment outcomes. Additionally, the company is developing new drugs and companion biomarkers for personalized medicine.

Dr. Jin-Xiong She, director of the MCG Center for Biotechnology and Genomic Medicine and president and CEO of the new company, said, "There are many wonderful scientific discoveries but the vast majority never translates into medical practice." Dr. She wants to help scientists close that gap. "That is what startup companies are trying to do: take discoveries to the next step so that big companies become interested."

Jinfiniti Biosciences, LLC focuses on commercialization of technologies and discoveries developed by the company founder, Dr. Jin-Xiong She. He is an authority in the fields of high throughput technologies in genomics, proteomics, and biomarker and drug development.

Related Links:
Jinfiniti Biosciences, LLC
Medical College of Georgia Life Sciences Business Development Center



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.